BURLINGTON, Massachusetts, May 26, 2026
Consano Bio, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for painful orthopedic disorders, has announced the successful dosing of the first patient in its Phase 1 clinical trial evaluating C-1101, a potential first-in-class, non-opioid biologic therapy for chronic sciatica, also known as chronic lumbosacral radiculopathy (LSR). The milestone represents a significant advancement for the company’s lead therapeutic program and highlights growing industry efforts to develop non-opioid alternatives for chronic nerve-related pain conditions.
The ongoing study, identified as C-1101-101, is a randomized, controlled, blinded, dose-escalation clinical trial designed to evaluate the safety and tolerability of C-1101 in patients suffering from chronic painful LSR. The multi-center study plans to enroll 24 patients across three sequential cohorts, with each participant receiving a single epidural injection of the investigational therapy. In addition to safety analysis, researchers will evaluate changes in pain severity, physical function, and sleep quality, all critical indicators of disease burden and therapeutic improvement in chronic sciatica patients.
C-1101 Targets the Root Cause of Chronic Sciatica
Unlike conventional pain management approaches that primarily address symptoms, C-1101 is designed as a disease-modifying biologic therapy intended to target the underlying nerve inflammation and tissue damage responsible for chronic sciatica. The investigational product is a platelet-derived multi-protein biologic therapeutic containing concentrated cytokines, growth factors, and matrix proteins aimed at stimulating the body’s natural healing processes directly at the site of nerve injury.
Chronic sciatica occurs when nerve roots in the lower spine become irritated or damaged, resulting in radiating pain extending from the lower back into the leg. Patients frequently experience numbness, weakness, tingling sensations, and severe mobility limitations that significantly impact quality of life. Despite affecting millions of patients worldwide, there are currently no FDA-approved pharmaceutical treatments specifically indicated for chronic sciatica.
Advertisement
Existing management strategies often rely on pain medications, epidural steroid injections, physical therapy, implantable spinal cord stimulators, or invasive surgical interventions. However, many patients continue experiencing inadequate symptom control, treatment-related complications, or temporary relief. Industry experts believe biologic therapies such as C-1101 may offer a new therapeutic approach capable of addressing the underlying pathology of chronic nerve-related pain rather than masking symptoms alone.
Preclinical Research Supports Therapeutic Potential
Consano Bio previously presented preclinical findings for C-1101 at the Orthopaedic Research Society (ORS) 2026 Annual Meeting, demonstrating anti-inflammatory activity and reparative effects across multiple translational models. According to the company, the data showed modulation of inflammatory pathways, activation of tissue repair mechanisms, reduced pain sensitivity in rodent neuropathy models, and beneficial effects on activated human immune cells.
The company believes these findings provide important scientific support for advancing C-1101 into clinical development as a potentially first-in-class therapy for chronic lumbosacral radiculopathy. Chief Executive Officer Andrew Hall described the successful dosing of the first patient as a historic milestone for both Consano Bio and the broader chronic pain treatment landscape.
Clinical investigators involved in the study also emphasized the urgent need for innovative treatment options. Dr. Paul Verrills, lead investigator for the Australian portion of the study and founder of MetroPain in Melbourne, noted that patients living with chronic LSR often face limited treatment options and persistent disability despite existing therapies.
Rising Demand for Non-Opioid Pain Therapies
The development of C-1101 comes amid increasing healthcare industry focus on reducing opioid dependency and advancing non-opioid therapies for chronic pain conditions. Lower back pain and chronic sciatica remain among the leading causes of disability globally and represent one of the most common reasons for opioid initiation in clinical practice.
Analysts believe regenerative biologic therapies capable of modulating inflammation and promoting nerve repair may become a major area of growth within orthopedic and pain management biotechnology sectors. If successful in clinical development, C-1101 could potentially establish a new therapeutic category for chronic sciatica and other debilitating nerve-related orthopedic disorders.
Source: Consano Bio press release
